TITLE

RECORD: No overall increase in CV risk with rosiglitazone

PUB. DATE
July 2009
SOURCE
Cardiology Today;Jul2009, Vol. 12 Issue 7, p9
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses a study on the association of rosiglitazone with the risk for overall cardiovascular morbidity or mortality.
ACCESSION #
42515399

 

Related Articles

  • Pioglitazone and Rosiglitazone: Effects of Treatment with a Thiazolidinedione on Lipids and Non Conventional Cardiovascular Risk Factors. Derosa, Giuseppe; Salvadeo, Sibilla A. T. // Current Clinical Pharmacology;May2008, Vol. 3 Issue 2, p77 

    The so-called central or upper-body obesity has been shown to play a key role in the development of insulin resistance and lipid abnormalities that commonly are associated with metabolic syndrome. Reducing free fatty acids (FFA) levels improves insulin resistance and lipid profile in metabolic...

  • The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Fidan, Evren; Onder Ersoz, H.; Yilmaz, Mustafa; Yilmaz, Hulya; Kocak, Mustafa; Karahan, Caner; Erem, Cihangir // Acta Diabetologica;Dec2011, Vol. 48 Issue 4, p297 

    Diabetic patients have a markedly increased risk of cardiovascular disease compared with non-diabetics. Two drug groups today target insulin resistance; biguanides and thiazolidinediones. In addition, these may have other effects on cardiovascular risk factors. The aim of this study was to...

  • Avandia Adcom Looks Down Track Toward Other Drugs. Serebrov, Mari // BioWorld Today;6/11/2013, Vol. 24 Issue 111, p1 

    The article reports that members of the Endocrinologic and Metabolic Drugs and the Drug Safety and Risk Management Advisory Committees of the U.S. Food and Drug Administration (FDA) voted to loosen the restrictions on prescribing Glaxosmithline plc's (GSK) diabetes drug, Avandia. They told FDA...

  • FDA Actions.  // Infectious Disease Alert;Nov2010 Clinical Bri, p2 

    The article reports on the drugs that were approved or restricted by the U.S. Food and Drug Administration (USFDA). Rosiglitazone, a drug for type 2 diabetes, was restricted due to its association with the increased risk of cardiovascular disease. The FDA has approved fingolimod an oral drug for...

  • Can the Electrophysiological Action of Rosiglitazone Explain its Cardiac Side Effects? Szebeni, A.; Szentandr�ssy, N.; Pacher, P.; Simk�, J.; N�n�si, P. P.; Kecskem�ti, V. // Current Medicinal Chemistry;Aug2011, Vol. 18 Issue 24, p3720 

    Recent large clinical trials found an association between the antidiabetic drug rosiglitazone therapy and increased risk of cardiovascular adverse events. The aim of this report is to elucidate the cardiac electrophysiological properties of rosiglitazone (R) on isolated rat and murine...

  • Pioglitazone is a Valid Alternative to Rosiglitazone. Derosa, Giuseppe // American Journal of Cardiovascular Drugs;2011, Vol. 11 Issue 6, p357 

    In 2000, two new thiazolidinediones, pioglitazone and rosiglitazone, were approved for the treatment of type 2 diabetes mellitus (T2DM). Administered as monotherapy or in combination with other antihyperglycemic agents, they represented an effective option for achieving or maintaining good...

  • FDA restricts access to Avandia due to increased cardiovascular risks.  // Drug Topics;Oct2010, Vol. 154 Issue 10, p21 

    The article focuses on the regulatory move of the U.S. Food and Drug Administration (FDA) in restricting the use of formulations that contain rosiglitazone to patients with Type 2 diabetes. It mentions that FDA's new restriction is a response on the growing risk of cardiovascular events on...

  • Smoke, stroke, and the stout woman. E.B. // Medical Update;Sep97, Vol. 21 Issue 3, p6 

    Reports that breathing other's cigarette smoke and obesity increase women's risk for cardiovascular diseases. Comparison of cardiac health status of women exposed and not exposed to cigarette smoke; Linkage of obesity with ischemic heart diseases.

  • Do changes in cardiovascular risk factors explain changes in mortality from stroke in Finland? Vartiainen, Erkki; Sarti, Cinzia // BMJ: British Medical Journal (International Edition);4/8/95, Vol. 310 Issue 6984, p901 

    Presents the results of a study which states that changes in the three main cardiovascular risk factors have caused a fall in the patient mortality rate in Finland. Observed changes in mortality from stroke during the past 20 years; Assessment of the levels of coronary risk factors; Calculation...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics